L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK. L-JNKI-1 has been shown to effectively inhibit JNK activity in in vivo studies. It is shown that Ang II induces a dose-dependent pressor response, which was significantly attenuated by JNK inhibition. It is also found that 10 μM L-JNKI-1 decreases phosphorylated c-Jun by 98% and phosphorylated Elk-1 by 100%.
| Molecular Weight | 3822.44 |
| Formula | C164H286N66O40 |
| Solubility (25°C) | Water 100 mg/mL |
| Storage | -20°C, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related JNK Products |
|---|
| YL5084
YL5084, a covalent JNK inhibitor, exhibits selectivity for JNK2 and JNK3 over JNK1 with IC50s of 70 nM, 84 nM and 2173 nM, respectively. YL5084 exhibits JNK2-independent antiproliferative effects and induces apoptosis in a JNK2-independent manner. |
| SR-3306
SR-3306 is a selective, potent, highly brain penetrant JNK inhibitor. |
| CC-90001
CC-90001 is a JNK (c-Jun N-terminal kinase) inhibitor that can be used as a Phase II clinical candidate to study idiopathic pulmonary fibrosis. |
| SU3327
SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. |
| L-JNKI-1
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
